Strs Ohio Purchases New Stake in Zoetis Inc. $ZTS

Key Points

• Strs Ohio has acquired a new stake in Zoetis Inc., purchasing 139,029 shares valued at approximately $22.89 million in the first quarter.
• Zoetis reported an earnings per share (EPS) of $1.76 for the last quarter, exceeding analysts' expectations, with revenue increasing by 4.2% year-over-year to $2.46 billion.
• Institutional ownership of Zoetis stands at 92.80%, with several investors adjusting their stakes, indicating significant confidence in the company's prospects.

Strs Ohio purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 139,029 shares of the company's stock, valued at approximately $22,891,000.

A number of other large investors have also added to or reduced their stakes in the business. Lindbrook Capital LLC raised its stake in Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after acquiring an additional 65 shares during the period. Quotient Wealth Partners LLC raised its stake in Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after acquiring an additional 72 shares during the period. Broadway Wealth Solutions Inc. raised its stake in Zoetis by 4.4% in the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after acquiring an additional 73 shares during the period. Menard Financial Group LLC raised its stake in Zoetis by 3.8% in the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock valued at $305,000 after acquiring an additional 75 shares during the period. Finally, Anchor Investment Management LLC raised its stake in Zoetis by 4.9% in the 1st quarter. Anchor Investment Management LLC now owns 1,618 shares of the company's stock valued at $266,000 after acquiring an additional 75 shares during the period. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Down 1.5%

Shares of NYSE ZTS opened at $148.33 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The stock has a market capitalization of $65.74 billion, a P/E ratio of 25.53, a PEG ratio of 2.42 and a beta of 0.89. The stock's fifty day moving average is $152.32 and its 200 day moving average is $157.31.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter last year, the business earned $1.56 earnings per share. Zoetis's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Argus reiterated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Zoetis presently has an average rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.